Navigation Links
Treating Alzheimer's disease with Yizhijiannao granules by inhibiting neuronal apoptosis
Date:8/13/2014

Previous studies have shown that Yizhijiannao granule can enhance cognitive performance in Alzheimer's disease patients and Alzheimer's disease-model mice. Further studies revealed that Yizhijiannao granule may exert its therapeutic effect by inhibiting neural cell apoptosis, reducing tau phos-phorylation and relieving neuroinflammation. Dr. Hong Zhu and colleagues who come from Third Xiangya Hospital of Central South University, China treated senescence-accelerated mouse prone 8 mice with Yizhijiannao granule, aiming to identify target-proteins of Yizhijiannao granule that were particularly related to the treatment of Alzheimer's disease. Thirty-seven differential protein spots were found in the temporal lobe area, and finally 10 protein spots were identified. These proteins are separately involved in the regulation of amyloid beta production, oxidative stress, neuroinflammation, regulation of tau phosphorylation, and regulation of neuronal apoptosis. The relevant study has been published in the Neural Regeneration Research (Vol. 9, No. 13, 2014).


'/>"/>

Contact: Meng Zhao
eic@nrren.org
86-138-049-98773
Neural Regeneration Research
Source:Eurekalert  

Page: 1

Related biology news :

1. Toward an oral therapy for treating Alzheimers disease: Using a cancer drug
2. Endocrine Press publishes guide to treating metabolic emergencies
3. Mechanism of cell death unraveled -- perspectives for treating inflammatory diseases
4. Marijuana shows potential in treating autoimmune disease
5. A new approach to treating peanut and other food allergies
6. Grape skin extract may soon be answer to treating diabetes
7. Mouse study points to potentially powerful tool for treating damaged hearts
8. Two researchers known for identifying and treating bubble boy disease honored by March of Dimes
9. Discovery leads to patent for novel method of treating traumatic brain injury
10. Worms and hot baths: Novel approaches to treating autism
11. Old drug may teach new tricks in treating infectious diseases, cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Treating Alzheimer's disease with Yizhijiannao granules by inhibiting neuronal apoptosis
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology: